Category News

Revolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio

Revolution Medicines a clinical-stage oncology company developing targeted therapies for RAS-driven cancers, announced significant clinical updates from its RAS(ON) inhibitor portfolio. The data, presented during an investor webcast, focused on the Phase 1 RMC-6236 monotherapy study in pancreatic ductal adenocarcinoma…

Read MoreRevolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio

GE HealthCare Showcases AI-Driven Innovations and Precision Care Solutions at RSNA 2024

At the 2024 Annual Meeting of the Radiological Society of North America (RSNA), held December 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) is presenting over 40 groundbreaking innovations. These include advanced AI-powered technologies aimed at optimizing patient care and enhancing…

Read MoreGE HealthCare Showcases AI-Driven Innovations and Precision Care Solutions at RSNA 2024